Skip to main content
Top
Published in: BMC Medicine 1/2022

01-12-2022 | SARS-CoV-2 | Research article

The University of Padua salivary-based SARS-CoV-2 surveillance program minimized viral transmission during the second and third pandemic wave

Authors: Daniela Basso, Ada Aita, Filippo Navaglia, Paola Mason, Stefania Moz, Alessio Pinato, Barbara Melloni, Luca Iannelli, Andrea Padoan, Chiara Cosma, Angelo Moretto, Alberto Scuttari, Daniela Mapelli, Rosario Rizzuto, Mario Plebani

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Background

The active surveillance of students is proposed as an effective strategy to contain SARS-CoV-2 spread and prevent schools’ closure. Saliva for molecular testing is as sensitive as naso-pharyngeal swab (NPS), self-collected and well accepted by participants. This prospective study aimed to verify whether the active surveillance of the Padua University employees by molecular testing of self-collected saliva is an effective and affordable strategy for limiting SARS-CoV-2 spread.

Methods

A surveillance program based on self-collection of saliva every 2 weeks (October 2020–June 2021) was conducted. Among 8183 employees of the Padua University, a total of 6284 subjects voluntarily took part in the program. Eight collection points guaranteed the daily distribution and collection of barcoded salivary collection devices, which were delivered to the laboratory by a transport service for molecular testing. Quarantine of positive cases and contact tracing were promptly activated.

Results

Among 6284 subjects, 206 individuals were SARS-CoV-2 positive (99 by salivary testing; 107 by NPS performed for contact tracing or symptoms). The cumulative SARS-CoV-2 incidence in this cohort was 3.1%, significantly lower than that of employees not in surveillance (8.0%), in Padua (7.1%) and in the Veneto region (7.2%). Employees with positive saliva results were asymptomatic or had mild symptoms. The levels of serum antibodies after 3 months from the infection were correlated with age and Ct values, being higher in older subjects with greater viral loads.

Conclusions

Salivary-based surveillance with contact tracing effectively allowed to limit SARS-CoV-2 contagion, also in a population with a high incidence.
Literature
1.
go back to reference Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. Cell. 2021;184:1127–32.CrossRef Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. Cell. 2021;184:1127–32.CrossRef
2.
go back to reference Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol. 2021;12:701501.CrossRef Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol. 2021;12:701501.CrossRef
3.
go back to reference Campbell JR, Uppal A, Oxlade O, Fregonese F, Bastos ML, Lan Z, et al. Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs. CMAJ. 2020;192:E1146–55.CrossRef Campbell JR, Uppal A, Oxlade O, Fregonese F, Bastos ML, Lan Z, et al. Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs. CMAJ. 2020;192:E1146–55.CrossRef
4.
go back to reference Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. Int J Infect Dis. 2020;100:112–6.CrossRef Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. Int J Infect Dis. 2020;100:112–6.CrossRef
5.
go back to reference Deckert A, Anders S, De Allegri M, Nguyen HT, Souares A, McMahon S, et al. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Trials. 2021;22:39–4.CrossRef Deckert A, Anders S, De Allegri M, Nguyen HT, Souares A, McMahon S, et al. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Trials. 2021;22:39–4.CrossRef
6.
go back to reference Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. J Clin Microbiol. 2021;59:e02881–20.PubMedPubMedCentral Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. J Clin Microbiol. 2021;59:e02881–20.PubMedPubMedCentral
7.
go back to reference Butler-Laporte G, Lawandi A, Schiller I, Yao M, Dendukuri N, McDonald EG, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021;181:353–60 Erratum in: JAMA Intern Med 2021;181:409.CrossRef Butler-Laporte G, Lawandi A, Schiller I, Yao M, Dendukuri N, McDonald EG, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021;181:353–60 Erratum in: JAMA Intern Med 2021;181:409.CrossRef
9.
go back to reference Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Cochrane COVID-19 diagnostic test accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3:CD013705.PubMed Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Cochrane COVID-19 diagnostic test accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3:CD013705.PubMed
10.
go back to reference Porte L, Legarraga P, Iruretagoyena M, Vollrath V, Pizarro G, Munita JM, et al. Rapid SARS-CoV-2 antigen detection by immunofluorescence – a new tool to detect infectivity. medRxiv. 2020;382:12–1. Porte L, Legarraga P, Iruretagoyena M, Vollrath V, Pizarro G, Munita JM, et al. Rapid SARS-CoV-2 antigen detection by immunofluorescence – a new tool to detect infectivity. medRxiv. 2020;382:12–1.
11.
go back to reference Drain PK, Ampajwala M, Chappel C, Gvozden AB, Hoppers M, Wang M, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: a clinical performance study. Infect Dis Ther. 2021;10:753–61.CrossRef Drain PK, Ampajwala M, Chappel C, Gvozden AB, Hoppers M, Wang M, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: a clinical performance study. Infect Dis Ther. 2021;10:753–61.CrossRef
12.
go back to reference Beck ET, Paar W, Fojut L, Serwe J, Jahnke RR. Comparison of Quidel Sofia SARS FIA test to Hologic Aptima SARS-CoV-2 TMA test for diagnosis of COVID-19 in symptomatic outpatients. J Clin Microbiol. 2021;59:e02727–0.CrossRef Beck ET, Paar W, Fojut L, Serwe J, Jahnke RR. Comparison of Quidel Sofia SARS FIA test to Hologic Aptima SARS-CoV-2 TMA test for diagnosis of COVID-19 in symptomatic outpatients. J Clin Microbiol. 2021;59:e02727–0.CrossRef
13.
go back to reference Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical evaluation of BD veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test. J Clin Microbiol. 2020;59:e02338–20.PubMedPubMedCentral Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical evaluation of BD veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test. J Clin Microbiol. 2020;59:e02338–20.PubMedPubMedCentral
14.
go back to reference Mendoza RP, Bi C, Cheng H-T, Gabutan E, Pagaspas GJ, Khan N, et al. Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities. EClinicalMedicine. 2021;38:101028.CrossRef Mendoza RP, Bi C, Cheng H-T, Gabutan E, Pagaspas GJ, Khan N, et al. Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities. EClinicalMedicine. 2021;38:101028.CrossRef
15.
go back to reference Aita A, Basso D, Cattelan AM, Fioretto P, Navaglia F, Barbaro F, et al. SARS-CoV-2 identification and IgA antibodies in saliva: one sample two tests approach for diagnosis. Clin Chim Acta. 2020;510:717–22.CrossRef Aita A, Basso D, Cattelan AM, Fioretto P, Navaglia F, Barbaro F, et al. SARS-CoV-2 identification and IgA antibodies in saliva: one sample two tests approach for diagnosis. Clin Chim Acta. 2020;510:717–22.CrossRef
16.
go back to reference Basso D, Aita A, Padoan A, Cosma C, Navaglia F, Moz S, et al. Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study. Clin Chim Acta. 2021;517:54–9.CrossRef Basso D, Aita A, Padoan A, Cosma C, Navaglia F, Moz S, et al. Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study. Clin Chim Acta. 2021;517:54–9.CrossRef
17.
go back to reference Azzi L. Saliva is the key element for SARS-CoV-2 mass screening. Clin Infect Dis. 2021;73:e566–8.CrossRef Azzi L. Saliva is the key element for SARS-CoV-2 mass screening. Clin Infect Dis. 2021;73:e566–8.CrossRef
18.
go back to reference Padoan A, Bonfante F, Cosma C, Di Chiara C, Sciacovelli L, Pagliari M, et al. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. Clin Chem Lab Med. 2021;59:1444–52.CrossRef Padoan A, Bonfante F, Cosma C, Di Chiara C, Sciacovelli L, Pagliari M, et al. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. Clin Chem Lab Med. 2021;59:1444–52.CrossRef
20.
go back to reference Thompson RN, Hill EM, Gog JR. SARS-CoV-2 incidence and vaccine escape. Lancet Infect Dis. 2021;21:913–4.CrossRef Thompson RN, Hill EM, Gog JR. SARS-CoV-2 incidence and vaccine escape. Lancet Infect Dis. 2021;21:913–4.CrossRef
21.
go back to reference Shields AM, Brown H, Phillips N, Drayson MT, Richter AA, Richter AG. Health care professionals’ confidence and preferences for diagnostic assays for SARS-CoV-2: a global study. Front Public Health. 2021;9:569315.CrossRef Shields AM, Brown H, Phillips N, Drayson MT, Richter AA, Richter AG. Health care professionals’ confidence and preferences for diagnostic assays for SARS-CoV-2: a global study. Front Public Health. 2021;9:569315.CrossRef
22.
go back to reference Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021;174:501–10.CrossRef Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021;174:501–10.CrossRef
23.
go back to reference Villar LM, Da Costa VD, Marques BCL, da Silva LL, Santos AC, Mendonça ACDF, et al. Usefulness of saliva samples for detecting SARS-CoV-2 RNA among liver disease patients. J Infect. 2021;82:e4–5.CrossRef Villar LM, Da Costa VD, Marques BCL, da Silva LL, Santos AC, Mendonça ACDF, et al. Usefulness of saliva samples for detecting SARS-CoV-2 RNA among liver disease patients. J Infect. 2021;82:e4–5.CrossRef
24.
go back to reference Melo Costa M, Benoit N, Dormoi J, Amalvict R, Gomez N, Tissot-Dupont H, et al. Salivette, a relevant saliva sampling device for SARS-CoV-2 detection. J Oral Microbiol. 2021;13:1920226.CrossRef Melo Costa M, Benoit N, Dormoi J, Amalvict R, Gomez N, Tissot-Dupont H, et al. Salivette, a relevant saliva sampling device for SARS-CoV-2 detection. J Oral Microbiol. 2021;13:1920226.CrossRef
25.
go back to reference Carmagnola D, Pellegrini G, Canciani E, Henin D, Perrotta M, Forlanini F, et al. Saliva molecular testing for SARS-CoV-2 surveillance in two Italian primary schools. Children (Basel). 2021;8:544. Carmagnola D, Pellegrini G, Canciani E, Henin D, Perrotta M, Forlanini F, et al. Saliva molecular testing for SARS-CoV-2 surveillance in two Italian primary schools. Children (Basel). 2021;8:544.
26.
go back to reference Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value and transmission of 2019-nCoV. Int J Oral Sci. 2020;12:11.CrossRef Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value and transmission of 2019-nCoV. Int J Oral Sci. 2020;12:11.CrossRef
27.
go back to reference Congrave-Wilson Z, Lee Y, Jumarang J, Perez S, Bender JM, Bard JD, et al. Change in saliva RT-PCR sensitivity over the course of SARS-CoV-2 infection. JAMA. 2021;326:1065–7.CrossRef Congrave-Wilson Z, Lee Y, Jumarang J, Perez S, Bender JM, Bard JD, et al. Change in saliva RT-PCR sensitivity over the course of SARS-CoV-2 infection. JAMA. 2021;326:1065–7.CrossRef
28.
go back to reference Shimamura Y, Komazawa H, Oikawa J, Furuta Y. Hospital-wide antigen screening for coronavirus disease in a tertiary reference center in Sapporo, Japan: a single-center observational study. Medicine (Baltimore). 2021;100:e28398.CrossRef Shimamura Y, Komazawa H, Oikawa J, Furuta Y. Hospital-wide antigen screening for coronavirus disease in a tertiary reference center in Sapporo, Japan: a single-center observational study. Medicine (Baltimore). 2021;100:e28398.CrossRef
29.
go back to reference Dorigatti I, Lavezzo E, Manuto L, Ciavarella C, Pacenti M, Boldrin C, et al. SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’. Nat Commun. 2021;12:4383–11.CrossRef Dorigatti I, Lavezzo E, Manuto L, Ciavarella C, Pacenti M, Boldrin C, et al. SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’. Nat Commun. 2021;12:4383–11.CrossRef
30.
go back to reference Padoan A, Dall'Olmo L, Rocca FD, Barbaro F, Cosma C, Basso D, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60–3.CrossRef Padoan A, Dall'Olmo L, Rocca FD, Barbaro F, Cosma C, Basso D, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60–3.CrossRef
Metadata
Title
The University of Padua salivary-based SARS-CoV-2 surveillance program minimized viral transmission during the second and third pandemic wave
Authors
Daniela Basso
Ada Aita
Filippo Navaglia
Paola Mason
Stefania Moz
Alessio Pinato
Barbara Melloni
Luca Iannelli
Andrea Padoan
Chiara Cosma
Angelo Moretto
Alberto Scuttari
Daniela Mapelli
Rosario Rizzuto
Mario Plebani
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
SARS-CoV-2
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02297-1

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue